Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H34O8 |
Molecular Weight | 474.5434 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14
InChI
InChIKey=IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
Molecular Formula | C26H34O8 |
Molecular Weight | 474.5434 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00959Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html
Sources: http://www.drugbank.ca/drugs/DB00959
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html
Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800003722
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00959 |
2.4 nM [EC50] | ||
Target ID: CHEMBL2034 Sources: http://www.ampoule.org.hk/pdf/advantan.pdf |
|||
Target ID: CHEMBL2111332 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15329590 |
1.07 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date1957 |
|||
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date1957 |
|||
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date1957 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
213 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
931 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23% |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg/kg single, intravenous Highest studied dose Dose: 1000 mg/kg Route: intravenous Route: single Dose: 1000 mg/kg Sources: |
unhealthy, 0-15 years Health Status: unhealthy Age Group: 0-15 years Sex: M+F Sources: |
|
1250 mg 1 times / day multiple, oral Highest studied dose Dose: 1250 mg, 1 times / day Route: oral Route: multiple Dose: 1250 mg, 1 times / day Sources: |
unhealthy, 18–59 years Health Status: unhealthy Age Group: 18–59 years Sex: M+F Sources: |
|
120 mg 1 times / week multiple, intramuscular Highest studied dose Dose: 120 mg, 1 times / week Route: intramuscular Route: multiple Dose: 120 mg, 1 times / week Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubs.acs.org/doi/abs/10.1021/mp900163d Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes | |||
Page: - |
yes | |||
Sources: http://epubs.surrey.ac.uk/855783/1/27606608.pdf Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin. | 1999 Jan |
|
Pulse methylprednisolone therapy for arthritis causing muscle weakness. | 1999 Sep |
|
Cytosine arabinoside induced acute interstitial nephritis in a patient treated for refractory anemia with excess of blasts in transformation. | 2000 Nov |
|
Stress-induced osteolysis of distal clavicle: imaging patterns and treatment using CT-guided injection. | 2001 |
|
Lupus nephritis in a child with AIDS. | 2001 Apr |
|
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus. | 2001 Apr |
|
Steroid-resistant kidney transplant rejection: diagnosis and treatment. | 2001 Feb |
|
[Evaluation of off-pump coronary artery bypass grafting based on systemic inflammatory response syndrome]. | 2001 Feb |
|
Glucocorticoid inhibition of neuropathic hyperalgesia and spinal Fos expression. | 2001 Feb |
|
Effective methylprednisolone dose in experimental crescentic glomerulonephritis. | 2001 Feb |
|
Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. | 2001 Feb 15 |
|
Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. | 2001 Feb-Mar |
|
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. | 2001 Feb-Mar |
|
Daclizumab induction therapy in combination with tacrolimus. | 2001 Feb-Mar |
|
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. | 2001 Feb-Mar |
|
Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. | 2001 Feb-Mar |
|
Successful withdrawal of steroid after renal transplantation. | 2001 Feb-Mar |
|
Preventive effects of lecithinized superoxide dismutase and methylprednisolone on spinal cord injury in rats: transcriptional regulation of inflammatory and neurotrophic genes. | 2001 Jan |
|
New treatment for postherpetic neuralgia. | 2001 Jan |
|
Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants. | 2001 Jan |
|
Osteonecrosis of the femoral head after allogeneic bone marrow transplantation. | 2001 Jan |
|
The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease. | 2001 Jan |
|
Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. | 2001 Jan 1 |
|
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. | 2001 Jan 27 |
|
Recurrent orbital inflammation from metastatic orbital carcinoid tumor. | 2001 Mar |
|
Steroids for acute exacerbations of COPD : how long is enough? | 2001 Mar |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/medrol.html
Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26339357
Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:43 GMT 2025
by
admin
on
Mon Mar 31 17:54:43 GMT 2025
|
Record UNII |
5GMR90S4KN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D008776
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201265
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
SUB12159MIG
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
220-863-9
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
SUB03256MIG
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
C87234
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
Methylprednisolone succinate
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
DB14644
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
2921-57-5
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
DTXSID80183466
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
100000091386
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
5GMR90S4KN
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
1771
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
1437009
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY | |||
|
16923
Created by
admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |